1721 related articles for article (PubMed ID: 15870086)
1. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
2. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
Menendez JA; Vellon L; Colomer R; Lupu R
Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
6. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
7. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
9. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9).
Menendez JA; Lupu R
Curr Pharm Biotechnol; 2006 Dec; 7(6):495-502. PubMed ID: 17168666
[TBL] [Abstract][Full Text] [Related]
10. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
[TBL] [Abstract][Full Text] [Related]
12. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
13. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
[TBL] [Abstract][Full Text] [Related]
15. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
16. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Colomer R; Lupu R
J Natl Cancer Inst; 2005 Nov; 97(21):1611-5. PubMed ID: 16264182
[TBL] [Abstract][Full Text] [Related]
17. Mediterranean diet, olive oil and cancer.
Colomer R; Menéndez JA
Clin Transl Oncol; 2006 Jan; 8(1):15-21. PubMed ID: 16632435
[TBL] [Abstract][Full Text] [Related]
18. Prolyl-isomerase Pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression.
Yun HJ; Kim JY; Kim G; Choi HS
Anticancer Res; 2014 Mar; 34(3):1409-16. PubMed ID: 24596388
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
